Search
Skip to Search Results- 18Cholesterol
- 9Arachidonic acid
- 3Cardiac hypertrophy
- 3Docosahexaenoic acid
- 2Astrocytes
- 2Atherosclerosis
- 1Aghazadeh Habashi, Ali
- 1Al Lawati, Hanan M
- 1Alabi, Adekunle
- 1Alrabeeah, Abdollah A. M.
- 1Alsaad,Abdulaziz M
- 1Beaulieu, Michael J.
-
Role of CYP-mediated Arachidonic Acid Metabolites in Development of Cardiac Hypertrophy and Chronic Doxorubicin-induced Cardiotoxicity
DownloadSpring 2013
Drug-induced cardiotoxicity is classified as a predisposing factor leading to cardiac hypertrophy and heart failure. Of importance, doxorubicin (DOX, adriamycin) is considered as an effective anticancer agent whose major limiting side effect is cardiotoxicity. Of importance, several studies...
-
The role of cytochrome P450 derived arachidonic acid metabolites against Angiotensin II-induced cardiac hypertrophy in Sprague Dawley rats and the RL-14 cell line
DownloadFall 2015
Several cytochrome P450 (CYP) enzymes and their arachidonic acid (AA) metabolites play essential roles in the maintenance of cardiovascular health, and their alteration gives rise to a number of cardiovascular diseases, including cardiac hypertrophy and heart failure. Recent data demonstrated...
-
The role of ezetimibe and simvastatin in modulating intestinal cholesterol transport, chylomicron profile and chylomicron-remnant uptake by the arterial wall in a rodent model of the metabolic syndrome
DownloadFall 2010
Intestinally derived chylomicron remnants (CM-r) may contribute to atherogenic dyslipidemia during the Metabolic Syndrome (Mets). However, the combined effects of ezetimibe (EZ) and simvastatin (SV) on post-prandial (PP) dyslipidemia during MetS remains unclear, nor is it known whether the...